NEW YORK, Sept. 24 – Solexa, a UK-based developer of high-throughput technology, has closed on roughly $12 million in its second round of venture capital financing, the company said on Monday.
Nick McCooke, Solexa's president and managing director, told GenomeWeb that the cash will be used to help create “the next generation of DNA sequencing tools.” McCooke reckons this recent cash infusion should be enough help the company meet that goal, which he said would likely happen within two years.
Schroder Ventre Life Sciences led the round, which was in negotiations since May, McCooke said.